shingles vaccine and covid vaccine timing

#SHINGLES VACCINE AND COVID VACCINE TIMING SKIN#
#SHINGLES VACCINE AND COVID VACCINE TIMING PLUS#

Ten days after receiving the first COVID-19 vaccine dose, she reported pain and a vesicular rash on the abdomen and back along the T10 dermatome, and was given acyclovir for 7 days. She had a history of varicella and had not been given the shingles vaccine. For the previous 2 years she had been treated with rituximab (Rituxan), mycophenolate mofetil (CellCept), and prednisone in doses of 7 mg/day.

#SHINGLES VACCINE AND COVID VACCINE TIMING PLUS#

The upadacitinib had been discontinued with the zoster eruption and she experienced a severe rheumatoid arthritis disease flare affecting multiple joints, and her arthritis treatment was subsequently switched to etanercept (Enbrel).Ĭase 4 was a 36-year-old woman with a long history of seropositive rheumatoid arthritis plus interstitial lung disease.

#SHINGLES VACCINE AND COVID VACCINE TIMING SKIN#

The antiviral was given for 3 days but was discontinued because of adverse effects, and the skin lesions healed slowly over a course of 6 weeks. Two days after receiving the second dose of the COVID vaccine, she reported pain and had a vesicular skin rash on the lower abdomen, inguinal area, buttock, and thigh, and was given valacyclovir. The symptoms resolved spontaneously within the subsequent 3 weeks without treatment, and she was given the second dose 4 weeks after the first. Three days after the first dose of the vaccine, she developed a vesicular skin rash with pruritus, along with low back pain and headache. She had a history of varicella and had not received a shingles vaccine. However, 'further surveillance of potential adverse effects following anti-COVID-19 vaccination in patients with rheumatic diseases is warranted,' she added.Ĭase 1 was a 44-year-old woman with Sjogren's syndrome who was being treated with hydroxychloroquine. 'We haven't seen any additional cases so far,' Furer told MedPage Today. The prevalence among patients was 1.2% versus none in controls, Furer and colleagues reported in Rheumatology.

This interim analysis included 491 patients and 99 controls, with events reported during the 6-week post-vaccination monitoring period. Little has been known about the safety and efficacy of the COVID-19 vaccines among patients with rheumatic diseases, because immunosuppressed individuals were not included in the initial clinical trials, they explained.Īccordingly, an observational study has been conducted at the Tel Aviv Medical Center and the Carmel Medical Center in Haifa, monitoring post-vaccination adverse events in patients with rheumatoid arthritis, spondyloarthropathies, connective tissue diseases, vasculitis, and myositis.

Shingles vaccine and covid vaccine timing